Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dose debate: which rituximab regimen works best for rare blistering disease?

NCT ID NCT07457944

Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at 275 pemphigus patients to see how different doses of rituximab affected disease control and relapse. Pemphigus is a rare autoimmune disease that causes painful blisters on skin and mucous membranes. Researchers tracked outcomes like flare-ups, side effects, and steroid use to find the safest and most effective dose.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rituximab
What this could lead to
If successful, this study could help doctors choose the best rituximab dose to control pemphigus with fewer side effects.
What could go wrong
This is a retrospective study, not a controlled trial, so results may be less reliable. Rituximab can cause serious infections or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

275 people

The number who actually took part.

Started

Jan 2019

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who had a clinical presentation of active pemphigus combined with immunological or pathological evidence, and received rituximab

Ages

18 to 100 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. patients with a diagnosis of pemphigus vulgaris or foliaceus in active stage based on guideline indicators, including typical clinical presentation, positive direct immunofluorescence microscopy findings, and/or detection of serum anti-Dsg3 and/or Dsg1 immunoglobin (Ig)G autoantibodies 2. follow-up for at least 6 months after initiation of rituximab therapy Exclusion Criteria: 1. Previous use of rituximab for other indications 2. concomitant use of other biological agents within 6 months (e.g. Dupilumab,IL-17,FcRn) 3. with a diagnosis of other variants of pemphigus besides PV and PF

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pemphigus disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pemphigus pemphigus foliaceus pemphigus vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pemphigus disease Rituximab (RTX)

Contacts and locations

Locations

  • Department of Dermatology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.